In clinical trials for the patients with multiple myeloma but received treatments, compared with the matched group (1.38/100 patients-year), the incidence rate of second primary tumors is rising in the lenalidomide (CAS: 191732-72-6)
/dexamethasone group (3.98/100 patients - year). Non-invasive second primary tumors include basal cells or squamous cell carcinoma.
Most aggressive second primary tumors are malignant solid tumors.
In the new diagnosis of multiple myeloma clinical trials, compared with the matched group (2.5%), the incidence rate of the second primary tumor in the lenalidomide (CAS: 191732-72-6)
is increased. For aggressive second primary tumors, among the patients who are receiving treatment (combination of lenalidomide (CAS: 191732-72-6)
and Melphalan, or Immediately taking lenalidomide
after using large dose melphalan and proceeding autologous stem cell transplantation (ASCT)), we found several cases of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and solid tumors. In some clinical trials, a number of B-cell malignancies (including Hodgkin's lymphoma) are found among the patients who have taken lenalidomide (CAS: 191732-72-6)
after proceeding an autologous stem cell transplant (ASCT).
The risk of a second primary tumor should be considered before taking lenalidomide (CAS: 191732-72-6)
. Standard cancer screening tools should be used before and during the treatment to assess the possibility of a second primary tumor and should treat it properly.
(CAS: 191732-72-6) from China Sinoway lenalidomide manufacturer
and get all info from this website!